Kornimate/medical-research-clean huggingface dataset:
non-returning catheter valve for reducing cauti

Conditions: Catheter Associated Urinary Tract Infection; Critically Ill Patients

Summary: this study was to determine efficacy of the non-returning catheter valve for reducing catheter associated urinary tract infection compared with conventional urine bag in critically ill patients.

non-returning catheter valve (generic name) used unometertm safetitm plus (trade name)

Eligibility criteria:
inclusion criteria: * the participants who age more than 18 year and admitted to the medical intensive care unit or intermediate care unit * all participants must be retained the urinary catheter. exclusion criteria: * the participants were diagnosed urinary tract infection before retention of the urinary catheter.

Keywords: non-returning catheter valve catheter associated urinary tract infection critically ill patients prevention
evaluation of sun protection education for kidney transplant recipients

Conditions: Unspecified Complications of Kidney Transplant; Disorder Related to Renal Transplantation

Summary: this study is being done to evaluate the effectiveness of a sun protection strategies workbook for kidney transplant recipients. since the medication taken to preserve the kidney transplant puts kidney transplant recipients at an increased risk of developing skin cancer. the program will help people learn about how to practice effective sun protection after the transplant.

cognitive interview about the sun protection strategies workbook will be performed with up to 25 kidney transplant recipients (ktr) who have participated in past surveys. a second phase of the study involves 156 ktrs that will be asked to take part in a randomized controlled trial evaluating the fully developed sun protective strategies workbook. kidney transplant recipients (ktrs) are at risk to develop skin cancer. adequate sun protection after transplantation can reduce the risk of developing skin cancer. in 2006, the national kidney foundation (nkf) found that sun protection education delivery and content varied among transplantation centers. clinicians rarely knew when to initiate education about skin cancer risks and prevention including timing and scope, and rarely demonstrated understanding of the importance of reminders for and repeated education of patients (national kidney foundation 2006). aims: 1. to explore culturally sensitive use of terms describing ethnic cultural perceptions of sun burning, pigment darkening after sun exposure and description of skin color by the amount of photo-protective pigment in the skin. 2. to pilot test the sun protection workbook with english speaking ktrs representing the 3 ethnic groups: white, black and hispanic. 3. to assess the effectiveness of an education intervention encouraging the use of sun protection strategies. 4. to explore understanding of the importance of sun protection and the ktrs confidence in their being able to practice sun protection.

Eligibility criteria:
inclusion criteria: * subjects with a history of kidney transplantation within the last 2-24 months * speaks english * can see to read * lives in the greater chicago area and can attend two study visits * 18-85 years old exclusion criteria: * unable to speak english * cognitive impairment or neurologic disease * dementia or insufficient cognitive skills to follow instructions provided at a sixth grade language level * has had a skin cancer

Keywords: kidney transplant renal transplant sun protection skin cancer
prevention of postpartum hemorrhage with tranexamic acid

Conditions: Postpartum Hemorrhage

Summary: postpartum hemorrhage is a significant contributor to maternal morbidity and mortality and is worldwide. txa has recently been proven to reduce mortality when given to women in setting of diagnosed pph. us obstetricians and anesthesiologists are hesitant to use txa in the peripartum period especially for prevention of pph due to uncertainty of an optimal dose and safety profile. the purpose of this study is to characterize the pharmacokinetics of txa when given prophylactically at time of delivery. in addition investigators will determine the pharmacodynamics of txa in the peripartum period.

conduct a prospective, open-label, dose finding pk study in 30 pregnant 3rd trimester women scheduled for non-emergent cesarean section who are at risk for hemorrhage. three doses of the drug will be administered in an escalating fashion by cohort with the lowest dose first. a maximum of 1 gram will be administered. txa serum levels at several time points after delivery will be assayed. a pk model will be constructed for determining the optimal txa dose administered at parturition.

Eligibility criteria:
inclusion criteria: * women who are undergoing medically indicated cesarean section at greater than 34+0 weeks gestation or women undergoing elective cesarean section at 39+0 weeks gestation in accordance with recommendations from the american congress of obstetricians and gynecologists * pregnant women with normal serum creatinine (serum creatinine \< 0.9) * women between the ages of 18 and 50 years old exclusion criteria: * patients younger than 18 or older than 50 * women with active thrombotic or thromboembolic disease * women with a history of arterial or venous thromboembolic event * women with inherited thrombophilia or preexisting conditions that predisposes them to thromboembolic events (i.e. lupus, antiphospholipid syndrome) * women with a subarachnoid hemorrhage * women with acquired defective color vision * history of seizure disorder * known renal dysfunction * multiple gestations (twin or triplet pregnancies) * hypersensitivity to tranexamic acid or anti-fibrinolytic therapy * history of liver dysfunction

Keywords: tranexamic acid postpartum hemorrhage
effect of chromium on blood sugar after sacroiliac joint injection

Conditions: Sacro Iliac Joint Pain; Diabetes

Summary: the aim of this study is to investigate whether oral chromium supplementation can decrease steroid-induced hyperglycemia in diabetic patients undergoing ultrasound-guided sacroiliac joint injections through a randomized controlled trial (rct).

one of the most prevalent complaints these days is sacroiliitis, which affects around 20% of the population. in roughly 10% to 27% of these cases, the sacroiliac joint has been identified as the major source of pain. due to the interrelated causes of facet joint and intervertebral disc pain, a precise diagnosis of sacroiliac joint pain is difficult. imaging methods, controlled local anesthetic blocks, history taking, and physical examinations can all be used to make a diagnosis. when people are unable to have surgery because of challenges with their health or other issues, steroids can be used to alleviate severe pain that has to be treated surgically. however, using steroids can have a number of negative consequences, including exhaustion, nausea, face flushing, and fever. one common steroid side effect is the elevation of blood glucose levels which can be challenging to diabetic patients. the hypothalamic-pituitary-adrenal (hpa) axis can be inhibited by the administration of steroids, which puts patients at risk for adrenal insufficiency and makes blood glucose management difficult , as it also raises the random blood sugar levels. additionally, it can increase insulin resistance and blood glucose levels by suppressing the activity of glucose metabolism and promoting gluconeogenesis. as a result, investigating a way to reduce the difficulty and minimize complications for people with diabetes is needed.. in comparison to those without diabetes mellitus (dm), patients with dm are more susceptible to vascular damage, joint and disk abnormalities, and degenerative changes. they also have a greater frequency of illnesses affecting the shoulders and spine. because steroid usage increases the risk of high blood glucose in individuals with diabetes mellitus, the active use of steroids in clinical practice is restricted. blood glucose rise following steroid injection in particular regions, such as the wrist, finger, shoulder, and knee, has been the subject of many investigations recently.

Eligibility criteria:
inclusion criteria: * adult patients (age ≥ 18 years). * diagnosed with diabetes mellitus. * scheduled for ultrasound-guided sacroiliac joint injections for pain management. exclusion criteria: * patients with contraindications to chromium supplementation like people with kidney or liver disorders or people with iron deficiency. * patients with a history of chromium allergy. * pregnant or lactating women. * patients with uncontrolled diabetes (hba1c \> 9%). * cardiac, renal, hepatic, coagulopathy. * lumbar spine deformity. * obesity bmi ( 35 kg/m²) * local infection.

Keywords: chromium sacroiliac joint injection
study to safety, tolerability and immunogenicity of eg-covii in healthy adult

Conditions: COVID-19

Summary: this is a phase i/iia study to assess the safety, tolerability and explore the immunogenicity of eg-covii in healthy adult volunteers

subjects will undergo a screening period beginning up to 2 weeks prior to enrollment, the vaccinations will be administered on week 0 and week 3, pre- and post-dose assessment, follow-up visits, and an end of study (eos) or early termination (et) visit (as applicable).

Eligibility criteria:
inclusion criteria: * able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before the first study-specific procedure; * healthy volunteers aged above 18 years at the time of screening; * have had at least authorised primary covid-19 vaccination(s) regardless of numbers of booster; * the last authorised covid-19 vaccination, the participants received, should be more than 16 weeks prior to the first ip vaccination; exclusion criteria: * participant with the evidence of covid-19 infection at screening (positive for covid-19 with rt-pcr test with nasal mid-turbinate specimen); * participant who has the history of covid-19 infection within 6 months from the first ip vaccination; * close contact with a person infected with covid-19 within 2 weeks prior to the first ip vaccination;
quality of recovery from mastectomy with and without pecs blocks

Conditions: Post Operative Pain; Quality of Recovery After Mastectomy

Summary: this is a prospective observational study. investigators want to understand post-operative recovery for patients undergoing mastectomy at northshore university healthsystem. some of these patients receive pecs blocks with liposomal bupivacaine and some do not receive a block. investigators want to know whether patients who receive a block have better post operative recovery and pain control than patients who do not receive one. investigators also want to understand whether pecs blocks with liposomal bupivacaine improves quality of recovery at 72 hours post operatively.

investigators plan to approach and consent 800 patients undergoing mastectomy, 400 with pecs blocks and 400 without. investigators will assess their quality of recovery using the qor 15 survey at 72 hours post operatively. in addition, investigators will also record vas scores immediately postoperatively and at 24, 48, and 72 hours postoperatively. the study team will also calculate the total morphine equivalents (mmes) required for each patient after 72 hours.

Eligibility criteria:
inclusion criteria: must be female must be \>18 years old and \< 90 years old must be able to consent in english or spanish may or may not have breast cancer (prophylactic mastectomy) must be undergoing unilateral or bilateral mastectomy of any type may choose to proceed with or without breast reconstruction exclusion criteria: * allergy to all narcotic or local anesthetic medications intake of any chronic opioids or pain medications preoperatively for a chronic condition or chronic use. subjects who received pecs blocks but whose block failed or is deemed not effective by an anesthesia provider as indicated by postoperative evaluation exam. vulnerable subjects (children, prisoners, pregnant women)
imaging hsp90 inhibitor auy922 on vegf-89zr-bevacizumab positron emission tomography (pet)

Conditions: Breast Cancer

Summary: inhibition of heat shock protein (hsp)90 is a new, promising treatment modality for cancer patients, particularly in the setting of resistance. a reliable read out system (biomarker) for the evaluation of early treatment effect is of great importance in the development of this treatment modality, and could contribute to customize this treatment for individual patients. so far, no reliable biomarker has been described for hsp90 effect. visualizing the effect of hsp90 on vascular endothelial growth factor (vegf) secretion in vivo in the patient, by whole body 89zr-bevacizumab uptake, can be of great importance in this respect, and may contribute to tailored made cancer treatment. the purpose of the present study is to evaluate the effect of hsp90 inhibition by auy922 on vegf by means of 89zr-bevacizumab pet.

this feasibility study is designed as a side study to the multicenter, international phase i-ii trial with hsp90 inhibitor auy922 (protocol cauy922a2101), as part of the biomarker assessment. in protocol cauy922a2101, section 4, the design of this phase i-ii trial is described (p37, 38). briefly, a dose-escalation study is performed according to phase i design in adult patients with advanced solid malignancies. this part is followed by a dose-expansion study according to a phase ii design. in the latter part, breast cancer patients are enrolled that are either refractory to hormone- or trastuzumab treatment (both treatment arms, n=40 patients), on the maximal tolerated dose of auy922 based on the phase i part of the study. patients with er positive, hormone therapy refractory breast cancer, will receive a 89zr-bevacizumab pet scan as part of the present side study protocol, which will be performed in collaboration with the royal marsden hospital (united kingdom). to this end, a 89zr-bevacizumab pet scan will be performed before (baseline) and during treatment with hsp90 inhibitor auy922, as described below. a minimum of six patients will be entered to evaluate whether the effect of hsp90 inhibition by auy922 can be detected with a 89zr-bevacizumab pet scan

Eligibility criteria:
inclusion criteria: * patients with er positive, hormone therapy refractory breast cancer * participation in the phase i-ii trial with hsp90 inhibitor auy922 (in- and exclusion criteria for the study with auy922 are described in protocol cauy922a2101, clinical trials no nct00526045a. exclusion criteria: * no participation in the phase i-ii trial with hsp90 inhibitor auy922

Keywords: heat shock protein breast cancer pet imaging bevacizumab
two approaches to lower the chances of recurrence of anal fistula after surgery

Conditions: Fistula in Ano

Summary: a total of 80 patients with complex fistula in ano of both genders were included. all patients in group a underwent a loose seton technique. in group b, video-assisted fistula tract surgery (vaafts) was performed.twice daily sitz baths, analgesics, and stool bulking agents (bran) were used in follow-up care. repeated examinations were carried out every four weeks and recurrence was noted at the end of three months

patients were equally allocated into two groups i.e. group a \& group b by lottery method. in both groups, the lower bowel was emptied by an enema about an hour before the operation. all patients in group a underwent the loose seton technique. the procedures were performed in the operating room with the patient in the lithotomy position. probing of the fistula tract was done with a metallic malleable probe. the incision was given from the external opening of the fistula to the anal verge, involving the skin, subcutaneous tissue, superficial part of the external sphincter, and superficial part of the internal sphincter. after the insertion of loose seton, a non-absorbable suture was left loosely and kept in situ for three months. in group b, video-assisted fistula tract surgery (vaafts) was performed. the patients were positioned in the lithotomy position. the fistuloscope was then introduced into the external opening and the procedure was performed, except for the closure of the internal opening, which was performed with either a "figure of eight" suture or an advancement flap, rather than using a stapler. the tracts were destroyed using electrocautery, the necrotic tissues were removed, and the external openings were cored out and left open for drainage. the patients were discharged the day following the procedure. twice daily sitz baths, analgesics, and stool bulking agents (bran) were used in follow-up care. repeated examinations were carried out every four weeks and recurrence was noted at the end of three months. the information (age, gender, duration of disease, bmi, diabetes mellitus, hypertension, place of living, and recurrence) was collected through pre-designed performa (annexure i).

Eligibility criteria:
1. inclusion criteria: * complex fistula in ano (as per operational definition) * with a duration of disease \>1 month, * either gender * history of previous surgery for fistula in ano 2. exclusion criteria: * pregnant females * bleeding disorder * history of pulmonary or systemic tuberculosis
daily magnesium-treatment of patients with chronic obstructive pulmonary disease

Conditions: COPD

Summary: the present study is part of a project titled 'magnesium in asthma and chronic obstructive pulmonary disease'. the hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease. the aim of this part of the project is to study the effect of a daily magnesium supplement for copd-patients


Eligibility criteria:
inclusion criteria: * copd-patients, grade moderate-severe (fev1 30-80 % of expected. fev1/fvc \< 0,7). exclusion criteria: * se-mg \> 2,00 mmol/l, smoking cessation less than 1 year prior to study start, submission to hospital within the last two years, submission to hospital with exacerbation during the study period, major changes in eating habits within three months prior to study start and during the study period of approx.one year various conditions (e.g. gastrointestinal disease, kidney disease, pregnancy/lactation) that may affect the study results.

Keywords: chronic obstructive pulmonary disease daily magnesium supplement eq-5d
predictive value of a snp signature and liquid biopsy in natural killer t-cell lymphoma

Conditions: Natural Killer T-cell Lymphoma

Summary: the purpose of this study is to determine the predictive value of a snp signature and liquid biopsy in patients with natural killer t-cell lymphoma.


Eligibility criteria:
inclusion criteria: * biopsy proved natural killer t-cell lymphoma * newly diagnosed patients exclusion criteria: * patients with biopsy samples unavailable
cftr modulator effects on bone and muscle in adults with cystic fibrosis

Conditions: Cystic Fibrosis; Bone Loss; Muscle Loss

Summary: study is looking at the effects of cystic fibrosis treatment on bone muscle.

cystic fibrosis (cf) is a complex multisystem genetic disease, with pulmonary and gastrointestinal consequences dominating the clinical picture. the life-expectancy of cf patients has increased through several therapeutic advances. although respiratory failure remains the major cause of mortality in cf, musculoskeletal impairments contribute to major morbidity. in the general population, musculoskeletal conditions are among the most common reasons for seeking medical care, and the risk of osteoporotic fracture increases with age. as the cf population ages, the morbidity related to musculoskeletal effects may increase. the etiology of cf related bone disease is multifactorial and includes effects of pancreatic insufficiency, poor nutritional status, vitamin d deficiency, glucocorticoid treatment, inflammation, hypogonadism, and sarcopenia, collectively resulting in attenuated bone mineral accrual and low bone density the effect of cystic fibrosis transmembrane conductance regulator (cftr) modulating drugs on bone disease in cf has not been evaluated. effects of cftr modulators may help counter the bone and muscle consequences of cf either directly by effects on bone or muscle cells, or indirectly by improved lung disease, improved nutritional status, decreased systemic inflammation or glucocorticoid use, or subsequent increases in physical activity. the rationale that underlies the proposed research is that better understanding of the bone and muscle effects of cftr modulator therapies will help guide strategies to optimize bone accrual, prevent osteoporosis and fractures, and improve functional outcomes in the aging cf population. set on the backbone of a longitudinal observational cohort study, the study will systematically and comprehensively evaluate changes in bone and muscle mass and strength from baseline to 12 month and 24 month time points among patients receiving cftr modulator therapies and also among controls not receiving cftr modulator therapies.

Eligibility criteria:
inclusion criteria: * documented, confirmed diagnosis of cf * age ≥18 years old * \>21 days since the start of their last pulmonary exacerbation at the baseline visit * provide signed written informed consent to participate exclusion criteria: * • estimated glomerular filtration rate (egfr) \<30 ml/min/m2 using the ckd-epi equation, * treatment with any osteoporosis medication within 6 months for oral agents or 1 year for intravenous or injectable agents (subjects may participate if therapy stopped earlier than these time periods). * current treatment with growth hormone or igf-1 * currently pregnant or lactating or planning plan on becoming pregnant during the duration of the study. * life expectancy less than 12 months * history of lung transplantation * conditions that in the opinion of the investigators would interfere with the ability to collect or interpret the data, or put the patient at higher safety risk from study procedures.
subcuticular continuous suture versus skin staples to reduce surgical site infections in colorectal surgery patients

Conditions: Surgical Wound Infections; Colorectal Surgery

Summary: a comparison of skin closure techniques (standard skin closure with staples versus a continuous (subcuticular) absorbable suture), to determine if this changes the rate of post operative wound infections in elective colorectal surgery patients.

in colorectal surgery, there has been a growing interest in the study of surgical site infections (ssi), with an outstanding variability of reported incidence, ranging from 3% up to 30% depending on the series. although general risk factors for infection have been identified, there is still a need to identify specific risk factors for colorectal surgery patients, to try to reduce these numbers. the technique and materials used for wound closure have been considered as interesting variables for study. main question of our study: is subcuticular (reabsorbable, continuous) suture better than skin staples for reducing wound ssis in colorectal surgery? the study is sponsored by the surgical infection society europe, and was awarded the sis-e fellowship for young investigators (2013)

Eligibility criteria:
inclusion criteria: * adults (age \>18), both genders. * elective colorectal surgery interventions * open surgery incisions and laparoscopic extraction incisions * incisions \>5cm, any location * intervention performed by a specialist colorectal surgeon * patient suitable for surgery in preoperative assessment * informed consent exclusion criteria: * emergency colorectal surgery * scheduled multiple surgical procedures * unsuitable preoperative assessment * other infections present/being treated. * incorrect application of standard surgical infection prevention measures (antibiotic prophylaxis, antibiotic treatment prior to surgery, intraoperative heat/o2/glycemic control,etc.) * inability to understand the study/sign informed consent

Keywords: surgical site infections skin closure techniques colorectal surgery